Canada · Delayed Price · Currency is CAD Aurora Spine Earnings Call Transcripts
Fiscal Year 2026
-
Significant product launches and portfolio expansion are set for 2026, including new cervical and lumbar implants, biologics, and SI joint solutions. Operational improvements, a growing sales team, and strong clinical research underpin a goal of surpassing $20 million in revenue.
Fiscal Year 2025
-
Record annual and Q4 revenues driven by ZIP, SiLO, and DEXA-L launches, with gross margin improvement and narrowed net loss. Expanded sales force and new product launches position the company for continued growth and cash flow positivity in 2026.
-
Q3 2025 revenue declined 7.1% year-over-year to $4.43M due to a product transition, but gross margin improved to 60.9%. Proprietary launches like Hydra ARO and Dexa L drove record October sales, and the company expects continued growth as adoption expands.
-
Minimally invasive spine devices and new product launches have driven strong revenue growth and margin expansion, with clinical evidence supporting adoption. The company is now focused on sales execution, expanding its sales team and market reach, and expects continued growth as new products roll out.
-
Q2 2025 saw a 10.2% revenue increase to $4.5M, with improved EBITDA and gross margins. Proprietary products like SiLO-TFX and DEXA-C drove growth, while new launches (Hydra Arrow, DEXA-L) are expected to boost results in late 2025. Cash position and collections remain stable.
-
Leadership highlighted a shift from R&D to commercialization, with a hybrid sales model and national expansion underway. Two major product launches—AERO facet fusion and lumbar DEXA—are expected to drive growth and market share in 2025.
-
Record Q1 revenue was driven by proprietary products and sales expansion, with SiLO TFX and DEXA-C showing strong growth. New product launches and clinical studies are expected to fuel further gains, and management targets at least 20% annual revenue growth in 2025.
-
The company reported strong revenue growth and its first positive net income in Q3 2024, driven by proprietary minimally invasive spine products. Key innovations like DEXA technology and expanding sales efforts position it for continued EBITDA positivity, cash generation, and a potential NASDAQ uplisting by 2026.
Fiscal Year 2024
-
Revenue grew 21% year-over-year in 2024, driven by proprietary products and a strengthened sales force, with SiLO TFX and ZIP 51 showing strong adoption. Gross margin and EBITDA improved, and the company expects at least 20% revenue growth in 2025, focusing on new product launches and cash flow positivity.
-
Achieved first profitable quarter with $4.8M revenue (up 21% YoY), driven by strong SiLO TFX and ZIP 51 sales, improved margins, and cost control. Outlook remains positive with new product launches and sales force expansion targeting $5M+ quarters in 2025.
-
Q2 2024 saw 14% revenue growth to $4.1M, improved gross margin to 62.4%, and a narrowed net loss. Sales of SiLO TFX and ZIP 51 surged, with strong cash flow and reduced receivables. Management targets a $5M quarter and expects profitability is within reach.